Evidence map›Paper›PMID 33163373›Full record

ArticleTranslational cancer research2020

Sarcopenia in aging, obesity, and cancer.

Jennifer A Ligibel, Kathryn H Schmitz, Nathan A Berger

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Impact of sarcopenia on outcomes following lumbar spine surgery for degenerative disease: an updated systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. The Influence of Muscle Morphology on Oncological Outcomes: A Review.Journal of frailty, sarcopenia and falls · 2025
    Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. The relationship between sarcopenia and serum irisin and TNF-α levels in newly diagnosed cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  16. Article
  17. Observational
  18. Respiratory Movements at Different Ages.Medicina (Kaunas, Lithuania) · 2023
    Article
  19. Role ofJapanese journal of radiology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Jennifer A LigibelDivision of Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kathryn H SchmitzDepartment Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Nathan A BergerDepartment Medicine, Biochemistry, Oncology, Genetics & Genome Sciences, Center for Science, Health and Society, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Case Western Reserve University · USHarvard University · USPennsylvania State University · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Resistance Training to Reduce Chemotoxicity in Colon CancerR01CA206196 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CAAN, BETTE J, MEYERHARDT, JEFFREY A · 2017 to 2021
$4.1M
Role of MYC-MIZ1 signaling and the inflammatory immune microenvironment in Triple-Negative Breast Cancer Racial DisparitiesP20CA233216 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LI, LI · 2018 to 2021
$3.6M
NCI NIH HHS P20 CA233216NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA206196NCI NIH HHS U54 CA163060
6 · The paper itself

Abstract

Sarcopenia, defined as loss of muscle mass, strength and physical performance, is a hallmark of aging and is invariably associated with perturbation of amino acid metabolism, increased muscle protein catabolism relative to anabolism, and loss of muscle fibers. Sarcopenia may be associated with general loss of body mass, or it may also occur along with obesity [sarcopenic obesity (SO)]. Although sarcopenia is associated with multiple comorbidities in older adults, its effects may even be more severe in patients with malignant disease where it has been shown to contribute to poor surgical outcomes, increased chemotherapy toxicity associated with both cytotoxic and targeted agents, as well as adversely impacting survival. While development of sarcopenia is a common age-related phenomenon, the associated catabolic processes appear to be promoted by physical inactivity, inadequate nutrition, and systemic low-grade inflammation, as well as intrinsic muscle and molecular changes, including mitochondrial dysfunction and impaired muscle stem cell regenerative capacity. Increased physical activity and adequate protein intake can reduce incidence and severity of sarcopenia in cancer patients, but many older cancer patients do not meet physical activity and nutrition recommendations, and cancer treatment can make it more difficult to make favorable lifestyle changes. Sarcopenia is discussed in terms of its adverse clinical consequences in older subjects and particularly, in older patients with cancer. Contributions of lifestyle, molecular, and cellular factors are likewise reviewed with suggestions for interventions to improve sarcopenia and its comorbid sequalae.

Indexed as

agingcancermuscle massobesitySarcopeniasarcopenic obesity (SO)

Identifiers

PMID33163373
PMCPMC7643855
OpenAlexW3035198120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.